Capricor Therapeutics Gets Type-B Meeting With FDA for CAP-1002
By Chris Wack
Capricor Therapeutics said Wednesday that it has an upcoming Type-B clinical meeting with the U.S. Food and Drug Administration planned for early in the third quarter.
During the planned meeting with the FDA, Capricor said it will outline its proposed path towards submission of a potential Biologics License Application and further discuss its ongoing clinical trial of CAP-1002 with the agency.
The company plans to use its CAP-1002 for the treatment of Duchenne muscular dystrophy
The regulatory pathway for CAP-1002 is supported by a Regenerative Medicine Advanced Therapy Designation, as well as a Orphan Drug Designation.
If Capricor receives market approval for CAP-1002 by the FDA, it would be eligible to receive a Priority Review Voucher based on its designation as a rare pediatric disease.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 07, 2023 09:40 ET (13:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing